Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
2seventy bio, Inc. - Common Stock
(NQ:
TSVT
)
4.400
+0.060 (+1.38%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 2seventy bio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Stocks That Hit 52-Week Lows On Thursday
December 22, 2022
Thursday's session saw 329 companies set new 52-week lows.
Via
Benzinga
Week in Review: VectorBuilder Raises $57 Million for Gene Therapy Delivery CDMO
October 30, 2022
Via
Talk Markets
Stocks That Hit 52-Week Lows On Tuesday
December 20, 2022
On Tuesday, 298 companies achieved new lows for the year.
Via
Benzinga
4 Analysts Have This to Say About 2seventy bio
November 08, 2022
Over the past 3 months, 4 analysts have published their opinion on 2seventy bio (NASDAQ:TSVT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
November 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Present Data from KarMMa-2 Study of Abecma (idecabtagene vicleucel) at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
November 03, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio and JW Therapeutics Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
October 27, 2022
From
2seventy bio, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
October 31, 2022
Upgrades
Via
Benzinga
2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multiple Myeloma Patients
September 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
August 31, 2022
From
2seventy bio, Inc.
Via
Business Wire
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
August 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy
August 10, 2022
Via
Benzinga
2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
August 10, 2022
From
2seventy bio, Inc.
Via
Business Wire
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma
August 10, 2022
From
Bristol Myers Squibb
Via
Business Wire
2seventy bio to Participate in Upcoming Investor Conferences
August 03, 2022
From
2seventy bio, Inc.
Via
Business Wire
The Top E-Commerce Company to Buy for Summer 2022
June 17, 2022
There's definitely a chance that struggling RealReal simply goes bankrupt, but its network effects could make it a buyout target.
Via
InvestorPlace
The 5 Top Profit & Protection Stocks to Buy for 2022
June 17, 2022
It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success.
Via
InvestorPlace
2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
June 06, 2022
From
2seventy bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
June 14, 2022
On Tuesday, 951 companies hit new 52-week lows.
Via
Benzinga
2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
May 12, 2022
From
2seventy bio, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
May 02, 2022
Upgrades
Via
Benzinga
2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therapy, at the AACR Annual Meeting
April 08, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio to Participate in CG Horizons in Oncology Virtual Conference
April 07, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
March 22, 2022
From
2seventy bio, Inc.
Via
Business Wire
2seventy bio Secures $170 Million in Private Placement Equity Financing
March 16, 2022
From
2seventy bio, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
March 15, 2022
During Tuesday's session, 454 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Taiwan Semiconductor (NYSE:TSM) was the largest company by...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
March 08, 2022
Tuesday's session saw 729 companies set new 52-week lows. Areas of Interest About Today's 52-Week Lows: Amazon.com (NASDAQ:AMZN) was the largest firm on a...
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
March 04, 2022
On Friday, 368 stocks hit new 52-week lows. Interesting Points From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...
Via
Benzinga
2seventy bio Announces Key Management Appointments
February 14, 2022
From
2seventy bio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.